It exhibits more prolonged inhibition of MAPK signaling compared to PD0325901, a well-known ATP-competitive MEK inhibitor.341 VS-6766, also known as CH5126766, is a first-in-class dual RAF-MEK inhibitor currently under investigation as a potential treatment for multiple myeloma and solid tumors harboring different RAS-RAF mutations. This evidence concerns the gene MAP2K7 and plasma cell myeloma.